Azerbaijan vs Macau, China: HIV-positive TB patients on ART (antiretroviral therapy)
Azerbaijan
100.0%
in 2024
Macau, China
100.0%
in 2024
Azerbaijan rank
1st
Macau, China rank
1st
HIV-positive TB patients on ART (antiretroviral therapy) over time
- Azerbaijan
- Macau, China
How they compare
Azerbaijan currently reports 100.0% against 100.0% in Macau, China, a difference of 0.0%.
The two have swapped places 5 times across 13 shared years of data; in 2011 it was Azerbaijan ahead.
Azerbaijan ranks 1st and Macau, China ranks 1st of 144 countries.
Azerbaijan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Azerbaijan | Macau, China | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 72.6% | 69.4% | 3.2% | Azerbaijan |
| 2020s | 98.2% | 78.4% | 19.8% | Azerbaijan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv-positive tb patients on art (antiretroviral therapy), Azerbaijan or Macau, China?
- Azerbaijan, at 100.0% against 100.0% in Macau, China as of 2024.
- What is the difference in hiv-positive tb patients on art (antiretroviral therapy) between Azerbaijan and Macau, China?
- 0.0%, with Azerbaijan ahead.
- How many years of comparable data are there for Azerbaijan and Macau, China?
- 13 years are reported by both, from 2011 to 2024.
- How do Azerbaijan and Macau, China rank globally for hiv-positive tb patients on art (antiretroviral therapy)?
- Azerbaijan ranks 1st and Macau, China ranks 1st of 144 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as HIV-positive TB patients on ART (antiretroviral therapy) (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.